TheraVet announced the first two dog patients treated with BIOCERA-VET? Bone Surgery in United Stated of America. These first patients mark the start of TheraVet clinical cases study on BIOCERA-VET? Bone Surgery in the USA, the objective of which is to collect additional safety and efficacy data in surgical procedures such as arthrodesis, osteotomy, fracture and Tibial Tuberosity Advancement (TTA). In this study, a minimum of thirty (30) patients will be treated with BIOCERA-VET? Bone Surgery. BIOCERA-VET? Bone Surgery commercialization in the USA is expected for 2022 first in the States of Texas, Florida and the Carolinas (north and south) - areas with high veterinary coverage -, before expanding to the whole of the United States. The two first patients included in this study were treated for a bilateral TTA and for a tarsal arthrodesis with BIOCERA-VET? Bone Surgery. Cases were performed by Dr. Hirshenson (DVM, DACVS-SA) and Dr. Morgan Hackett (DVM) from Triangle Veterinary Referral Hospital (North Carolina) based in the Research Triangle park known as one of the largest US research parks housing hundreds of companies and in a state ranked in the top 10 states with the highest number of vets and private practices. A pilot study performed in Europe earlier this year has been assessing the efficacy and safety of BIOCERA-VET? in arthrodeses (i.e., bone fusion) in a total of 29 dogs (7 tarsus and 22 carpus) among which 16 were treated with autografts and 13 with BIOCERA-VET?. A blinded radiological analysis was performed by an independent surgeon at 4 and 8 weeks after surgery: radiographs were scored from 0 (no visible sign of fusion) to 3 (total fusion). Bone fusion induced by BIOCERA-VET? was as good as the one induced by bone autograft (respective mean scores of 1.70 vs 1.41 (p>.05) at 4 weeks and of 2.08 vs 1.88 (p>0.05) at 8 weeks). However, the safety evaluation showed a lower rate of complications with BIOCERA-VET? as compared to autograft. Together, this translates into an excellent efficacy-safety profile for TheraVet?s bone substitute.